Precision-tuned immune agonists — targeted innovation

StradBio is creating the next generation of immunotherapies for cancer and inflammatory diseases.

Through precision-tuned cytokine mimetics, targeting, and logic gates, we are building drugs that can deliver potent activation of immune cells where they are needed most, minimizing side effects.

Our goal is to put your immune system to work, so that you can work on life.

The Solution:
StradBio’s Daiad^TM Platform Widening the therapeutic index

Computationally-designed, hyperstable cytokine mimetics as novel payloads
Split payloads are targeted to create ‘AND’ logic gates without sacrificing potency
Only active when payload is reconstituted in the tumor microenvironment
Potent, precise, safe by design

Publications

De novo design of potent and selective mimics of IL-2 and IL-15

Nature. 2019 January

A First-In-Human Phase 1 Study of NL-201 in Patients with Relapsed or Refractory Cancer

Journal for ImmunoTherapy of Cancer. 2021 November

A split, conditionally active mimetic of IL-2
reduces the toxicity of systemic cytokine
therapy

Nature Biotechnology. October 2022

Conditional Immune Activation with Daiad-2/15: a Targeted, Hyperpotent IL-2/IL-15 Agonist with an Engineered Logic Gate

Computationally-designed, hyperstable cytokine mimetics as novel payloads
Split payloads are targeted to create ‘AND’ logic gates without sacrificing potency
Only active when payload is reconstituted in the tumor microenvironment
Potent, precise, safe by design

Pipeline

Platform

Daiad-2/15

Daiad-TRA

Daiad-Broad

Indication

Oncology

Autoimmunity

Broad

Research

Lead Optimization

IND Enabling

Research

Lead Optimization

IND Enabling

Daiad-2/15

Oncology

Daiad-TRA

Autoimmunity

Daiad-Broad

Broad

Team

Jonathan Drachman, MD

Chief Executive Officer and Co-Founder

Jonathan has 20 years of biotechnology experience, including 14 years at Seattle Genetics (2004-18), serving in multiple roles, including Chief Medical Officer and EVP of Research and Development. Subsequently, Jonathan was CEO and Co-Founder of Neoleukin Therapeutics, a spin-out from the Institute of Protein Design. Dr. Drachman attended Harvard Medical School and then trained in internal medicine and medical oncology at the University of Washington, where he ran an academic research lab until 2004. Jonathan has been a Board member of multiple public and private biotech companies.

Mark Branum, Ph.D

Chief Technical Officer and Co-Founder

Dr. Mark Branum is Chief Technical Officer and a Founder of StradBio and leads protein sciences, CMC and operations. An experienced leader in biopharmaceutical startup companies with 20 years of experience moving programs from research into clinical trials. Dr. Branum held leadership roles in Theraclone Sciences, OncoResponse, Immune Design and Highlight Therapeutics. Prior to his career in industry Dr. Branum earned a Ph.D in chemistry from the University of Minnesota and was a postdoctoral fellow in the laboratory of Nobel laureate Aziz Sancar.

Alexander (Sasha) Astrakhan, Ph.D

Vice President of Research

Sasha brings 15 years of industry experience to StradBio and leads the early development of our innovative cytokine mimetics. With a Ph.D. in Immunology from the University of Washington, Dr. Astrakhan has a strong track record in preclinical development of therapies for oncology and autoimmune indications.